SATISFY‐JP, a phase II multicenter open‐label study on Satralizumab, an anti‐IL‐6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune‐responsive‐phenotype: Study protocol

Pulmonary arterial hypertension (PAH), an intractable disease with a poor prognosis, is commonly treated using pulmonary vasodilators modulating the endothelin, cGMP, and prostacyclin pathway. Since the 2010s, drugs for treating pulmonary hypertension based on mechanisms other than pulmonary vasodil...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Yuichi, Takeyasu, Rika, Takata, Tomohiro, Miyazaki, Naoki, Takemura, Ryo, Wada, Michihiko, Tamura, Yudai, Abe, Kohtaro, Shigeta, Ayako, Taniguchi, Yu, Adachi, Shiro, Inami, Takumi, Tsujino, Ichizo, Tahara, Nobuhiro, Kuwana, Masataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278205/
https://www.ncbi.nlm.nih.gov/pubmed/37342675
http://dx.doi.org/10.1002/pul2.12251

Ejemplares similares

Ejemplares similares